

: 100010517

Clear all data

RECEIVED
SECRETARY OF THE
PUBLIC

06 FEB 15 AM 9:54

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name Dutko Worldwide, Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported 412 First Street SE Suite 100 Washington DC 20003 USA			
3. Principal place of business (if different than line 2) City State/Zip or Country			
4a. Contact Name Mr. Stephen Brown		b. Telephone number (202) 484-4884	
		c. E-mail sbrown@duikoworldwide.com	
7. Client Name <input type="checkbox"/> Self NABI Biopharmaceuticals		5. Senate ID # 12868-6093	
		6. House ID # 32229361	

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31)9. Check if this filing amends a previously filed version of this report ☐10. Check if this is a Termination Report ☐ ⇨ Termination Date _____

11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>75,000</u> Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	13. Organizations EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> ⇨ \$ _____ 14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. <input type="checkbox"/> Method A. Reporting amounts using LDA definitions only <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code
--	---

Edit >

Signature _____ Date _____

Printed Name and Title Mark Irion - Chief Executive Officer

0000131440



Registrant Name Dutko Worldwide, Inc.

Client Name NABI Biopharmaceuticals

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED - Medical/Disease Research/Clinical Labs (one per page)

16. Specific lobbying issues

Monitor legislation and advise client on regulatory and legislative issues within the Medicare program

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House of Representatives
Senate
Department of Health & Human Services
White House

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Gary	Andres	
Cartier	Esham	
Darren	Willcox	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____

Date _____

Printed Name and Title Mark Irion - Chief Executive Officer

